• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 4. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Recent Advances in the Application of 5-Bromo-6-fluoropicolinonitrile (CAS: 1806849-64-8) in Chemical Biology and Pharmaceutical Research

5-Bromo-6-fluoropicolinonitrile (CAS: 1806849-64-8) has emerged as a critical intermediate in the synthesis of novel bioactive compounds, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies highlight its utility in constructing heterocyclic scaffolds, which are pivotal in drug discovery. This compound's unique bromo-fluoro substitution pattern enhances its reactivity and selectivity, making it a valuable building block for medicinal chemistry applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 5-Bromo-6-fluoropicolinonitrile in the synthesis of potent JAK2 inhibitors. The researchers leveraged its electrophilic properties to achieve high-yield cross-coupling reactions, enabling the rapid assembly of diverse compound libraries. The resulting inhibitors exhibited nanomolar potency and improved metabolic stability, underscoring the compound's role in optimizing drug candidates.

Further investigations have explored its application in PET (positron emission tomography) tracer development. A team at MIT reported the incorporation of 5-Bromo-6-fluoropicolinonitrile into a radiolabeled probe for imaging aberrant kinase activity in tumors. The probe's high specificity and low background signal were attributed to the strategic placement of the bromo and fluoro substituents, which minimized off-target interactions.

In addition to its pharmacological applications, 5-Bromo-6-fluoropicolinonitrile has been employed in agrochemical research. A 2024 patent by Syngenta disclosed its use in synthesizing next-generation fungicides with enhanced environmental persistence. The compound's stability under UV exposure and hydrolytic conditions was a key factor in its selection for field trials.

Ongoing research is investigating the compound's potential in covalent inhibitor design. Computational modeling suggests that the nitrile group can serve as a warhead for targeting cysteine residues in disease-relevant proteins. Preliminary data presented at the 2024 ACS Spring Meeting showed promising activity against SARS-CoV-2 main protease, opening new avenues for antiviral development.

The commercial availability of 5-Bromo-6-fluoropicolinonitrile has increased significantly, with major suppliers like Combi-Blocks and Sigma-Aldrich offering GMP-grade material. This accessibility is accelerating its adoption in both academic and industrial settings. However, challenges remain in scaling up synthetic routes while maintaining cost-effectiveness, particularly for multi-kilogram quantities required in clinical-stage programs.

• 2806721-30-0(4-bromo-6-fluoropicolinonitrile-3,5-d2)
• 1804381-07-4(4-Bromo-6-fluoropicolinonitrile)
• 632628-07-0(3,5-Dibromo-2-fluoro-6-methylpyridine)
• 375368-78-8(3-Bromo-2-fluoro-6-picoline)
• 2613382-60-6(1-(5-Bromo-6-fluoropyridin-2-yl)methanamine)
• 2294950-38-0(3-bromo-2-fluoro-6-(methyl-d3)pyridine-4,5-d2)
• 1565634-54-9(3-Bromo-6-fluoropicolinonitrile)
• 2613388-54-6(1-(5-bromo-6-fluoropyridin-2-yl)methanamine hydrochloride)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)